A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin(R)) in a Healthy US Adult Population
Latest Information Update: 27 Sep 2021
At a glance
- Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary)
- Indications Hepatitis E
- Focus Adverse reactions; Pharmacodynamics
- 24 Sep 2020 Status changed from active, no longer recruiting to completed.
- 16 Jul 2020 Planned End Date changed from 30 Apr 2020 to 30 May 2021.
- 16 Jul 2020 Planned primary completion date changed from 30 Apr 2020 to 30 May 2021.